中糧科技(000930.SZ):擬實施年產3萬噸年丙交酯搬遷項目
格隆匯2月12日丨中糧科技(000930.SZ)公佈,生物可降解材料是中糧生物科技股份有限公司轉型升級的重要方向,本項目可解決丙交酯關鍵環節的瓶頸問題,補齊聚乳酸產業鏈短板。本次搬遷後,項目預期經營情況將有所改善,爲產業後續規模化發展奠定更好基礎。項目名稱:中糧科技3萬噸/年丙交酯搬遷項目。本項目建設內容:丙交酯車間及動能車間、氣相熱媒罐區、乳酸原料罐區、循環水泵站等配套設施。本項目投資總額:65,545.93萬元,其中建設投資61,560.07萬元,建設期利息1,043.30萬元,流動資金2,942.56萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.